Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Plasminogen activator, recombinant

Tissue plasminogen activator, recombinant human (rhtPA)... [Pg.692]

Fig. 2. Outline of possible steps in the recovery and purification sequence for recombinant tissue plasminogen activator derived from recombinant CHO... Fig. 2. Outline of possible steps in the recovery and purification sequence for recombinant tissue plasminogen activator derived from recombinant CHO...
Fig. 4. Fibrinolytic system where SCUPA is single-chain urokinase plasminogen activator rTPA is recombinant tissue plasminogen activator APSAC is acylated plasminogen streptokinase activator complex SK is streptokinase and UK is urokinase. Fig. 4. Fibrinolytic system where SCUPA is single-chain urokinase plasminogen activator rTPA is recombinant tissue plasminogen activator APSAC is acylated plasminogen streptokinase activator complex SK is streptokinase and UK is urokinase.
Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boy sen G, Bluhmki E, Hoxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995 274 1017-1025. [Pg.34]

Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 282 2019-2026 [see comment]. [Pg.35]

Stroke is the leading cause of major long-term disability in adults and the third leading cause of death in the United States. On average, a new stroke occurs every 45 seconds. Thrombolytic therapy with intravenous recombinant tissue-plasminogen activator (IV rt-PA) is the most effective treatment for acute ischemic stroke. In this chapter, we review the rationale for thrombolysis in acute ischemic stroke, clinical evidence supporting the use of thrombolytics, and the application of thrombolysis in practice. [Pg.39]

Del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Eurlan AJ, Ferhert A, Alberts MJ, Zivin JA, Wechsler L, Busse O. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992 32 78-86. [Pg.55]

Papadopoulos SM, Chandler WF, Salamat MS, Topol EJ, Sackellares JC. Recombinant human tissue-type plasminogen activator therapy in acute thromboembolic stroke. J Neurosurg. 1987 67 394-398. [Pg.56]

Kwiatkowski TG, Libman RB, Frankel M, Tilley BC, Morgenstem LB, Lu M, Broderick JP, Lewandowski CA, Marler JR, Levine SR, Brott T. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. New England Journal of Medicine. 1999 340 1781-1787. [Pg.56]

Larrue V, von Kummer RR, Muller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator A secondary analysis of the european-australasian acute stroke study (ECASS II). Stroke. 2001 32 438 1. [Pg.57]

Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice The Multicenter rt-PA Stroke Survey. Circulation. 2002 105 1679-1685. [Pg.58]

Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke A pooled analysis of randomized clinical trials. Stroke. 2005 36 62-65. [Pg.58]

Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke a population-based study. Stroke. 2004 35 e27-29. [Pg.61]

Wiese KM, Talkad A, Mathews M, Wang D. Intravenous recombinant tissue plasminogen activator in a pregnant woman with cardioembolic stroke. Stroke. 2006 37 2168-2169. [Pg.61]

Thirumalai SS, Shubin RA. Successful treatment for stroke in a child using recombinant tissue plasminogen activator. J Child Neurol. 2000 15 558. [Pg.62]

Wolpert SM, Bmckmann H, Greenlee R, Wechsler L, Pessin MS, del Zoppo GJ. Neuror-adiologic evaluation of patients with acute stroke treated with recombinant tissue plasminogen activator. The rt-PA Acute Stroke Smdy Group. Am J Neuroradiol 1993 14 3-13. [Pg.91]

Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D, Kanter D, Jauch E, Carrozzella J, Spilker J, Broderick J. Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischemic stroke. Stroke 2000 31 2552-2557. [Pg.92]

Zeumer H, Ereitag HJ, Zanella E, Thie A, Arning C. Local intra-arterial fibrinolytic therapy in patients with stroke urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993 35 159-162. [Pg.94]

Grotta J. Combination therapy stroke trial recombinant tissue-t3fpe plasminogen activator with/without lubeluzole. Cerebrovasc Dis 2001 12 258-263. [Pg.119]

See other pages where Plasminogen activator, recombinant is mentioned: [Pg.43]    [Pg.505]    [Pg.521]    [Pg.34]    [Pg.173]    [Pg.43]    [Pg.505]    [Pg.521]    [Pg.34]    [Pg.173]    [Pg.42]    [Pg.45]    [Pg.54]    [Pg.206]    [Pg.180]    [Pg.144]    [Pg.144]    [Pg.310]    [Pg.310]    [Pg.311]    [Pg.506]    [Pg.428]    [Pg.354]    [Pg.407]    [Pg.2]    [Pg.11]    [Pg.32]    [Pg.53]    [Pg.63]    [Pg.132]   


SEARCH



Plasminogen

Plasminogen activation

Plasminogen activators

© 2024 chempedia.info